Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Job title: MD
Dr Tschöpe is Professor of Medicine and Cardiology and the Vice Director of the Department of Cardiology, Charité, Campus Virchow Klinikum, Berlin, guiding the cardiomyopathy programme. His main research interests are the potential of cell therapies to cure heart failure and the role of the immune system in heart failure. View more
Cardiac Toxicity of Cancer Chemotherapy
Author(s): Aarti Asnani Start date: Aug 08, 2017

Heart Failure
Author(s): Aarti Asnani , Randall T Peterson Added: 3 years ago
Survival rates among patients diagnosed with cancer have improved dramatically over the past few decades. In 2016, there were an estimated 16 million cancer survivors in the United States, a number expected to increase to 20 million over the subsequent decade.1 One-third of these patients will survive at least 5 years after their initial cancer diagnosis, largely due to cancer therapies that are… View more

Heart Failure

CV Disease in Special Populations
Mark Linch
Job title: Associate Professor and Consultant in Uro-Oncology
Dr Mark Linch is an Associate Professor at University College London (UCL) Cancer Institute, where he leads the Urological Cancer Biology Group, and Honorary Consultant Medical Oncologist. Dr Linch trained in medical oncology at the Royal Marsden Hospital (RMH), London. In 2012 he was awarded a PhD in Cancer Cell Biology from UCL and the Cancer Research UK London Research Institute (LRI), now… View more
Author(s): Kiran K Khush , Sharon A Hunt Added: 3 years ago
The field of heart transplantation has evolved tremendously since Alexis Carrel first explanted a canine heart and anastomosed it to the carotid artery and jugular vein of a recipient dog in 1905.1 In 1960, Norman Shumway and Richard Lower at Stanford described a technique for orthotopic canine heart transplantation and demonstrated adequate physiologic function of the denervated heart.2 Their… View more

Vascular Disease and Surgery
POTS-associated Conditions and Management Strategies
Author(s): Rebecca S Steinberg , Weston Dicken , Alexis Cutchins Added: 7 months ago

Demographic

Electrophysiology & Arrhythmia
Author(s): Gil J Gross Added: 3 years ago
Rhythm disorders, independent of structural congenital heart disease, have been described with myriad pediatric syndromes.Reviewing all pediatric syndromes associated with rhythm disorders is beyond the scope of this text.However, arrhythmia as a common or defining clinical feature of a pediatric syndrome is relatively rare. A representative sample of pediatric syndromes that prominently feature… View more

Electrophysiology & Arrhythmia
AHA 2018: The Cardiovascular Inflammation Reduction Trial (CIRT)
Author(s): Paul M Ridker Added: 5 years ago
Prof Paul M Ridker (Brigham and Women’s Hospital, Boston, US) discusses The Cardiovascular Inflammation Reduction Trial (CIRT) - Low Dose Methotrexate for the Prevention of Atherosclerotic Events.Filmed on site at AHA 2018 by Radcliffe Cardiology. View more

Electrophysiology & Arrhythmia
Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
Author(s): Katelyn Storey , Scott W Sharkey Added: 3 years ago
During the past 25 years, takotsubo syndrome (TS) has emerged as an important form of acute myocardial injury characterized by a distinctive regional left ventricular (LV) contraction abnormality, often with marked reduction of the LV ejection fraction, and typically completely reversible. At presentation, TS is often indistinguishable from acute coronary syndrome, yet its occurrence is… View more

Heart Failure
ACC 2021: Findings From the RESCUE Trial
Author(s): Paul M Ridker Added: 2 years ago
In this video, Dr Paul Ridker (Brigham and Women’s Hospital, Boston, MA, US) discusses the findings from the RESCUE trial, which aimed to assess whether Ziltivekimab is effective in reducing cardiovascular biomarkers in high-risk patients with chronic kidney disease. Dr Ridker also outlines the upcoming ZEUS outcomes study following the results of this trial. Questions: 1. What does this trial… View more

Prevention & Chronic Conditions

CV Disease in Special Populations